Brawn Biotech Ltd

Brawn Biotech Other Announcement

Brawn Biotech informed the exchange that it has issued letters to shareholders regarding the 41st AGM notice and annual report access.

Brawn Biotech Annual General Meeting

Brawn Biotech Ltd has filed the notice for its 41st Annual General Meeting, scheduled to be held on September 29, 2026, via video conferencing.

Brawn Biotech Q1 FY27 Results: Net Profit ₹0.2 Cr, Up 0.0% YoY

Brawn Biotech Ltd reported revenue from operations of ₹6.1 Cr (+5.2% YoY) and net profit of ₹0.2 Cr (+0.0% YoY) for Q1 FY27.

Key figure

Net profit ₹0.2 Cr · +0.0% YoY

Brawn Biotech Board Meeting Date

Brawn Biotech Ltd has scheduled a Board Meeting for August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.

Brawn Biotech Other Announcement

Brawn Biotech Ltd notified BSE regarding the non-applicability of Regulation 24A for Annual Secretarial Compliance Report. The company remains below the mandatory reporting thresholds for capital and networth.

Brawn Biotech Q4 FY26 Results: Net Profit ₹0.6 Cr, Down 53.8% YoY

Brawn Biotech Ltd reported revenue from operations of ₹2 Cr (-65.5% YoY) and net profit of ₹0.6 Cr (-53.8% YoY) for Q4 FY26.

Key figure

Net profit ₹0.6 Cr · -53.8% YoY

Brawn Biotech Financial Results

Brawn Biotech Ltd reported standalone annual revenue of ₹17.43 Crore for FY26. The Board approved these audited financial results during its meeting on May 29, 2026.

Value

₹17.43 Cr

Brawn Biotech Board Meeting Date

Brawn Biotech scheduled a board meeting for May 29, 2026, to approve audited FY2026 financial results. The trading window remains closed until June 1, 2026.

Brawn Biotech Debt & Borrowing

Brawn Biotech Limited confirmed it does not meet the SEBI criteria to be classified as a Large Corporate as of March 31, 2025. The company reported zero outstanding borrowings under the framework. This annual regulatory disclosure ensures compliance with SEBI debt-raising norms for the 2026 financial year.

Brawn Biotech Other Announcement

Brawn Biotech Ltd submitted the compliance certificate under Regulation 74(5) of SEBI (DP) Regulations for the quarter ended March 31, 2026. The Registrar, RCMC Share Registry, confirmed that security certificates received for dematerialisation were processed and mutilated within the required 15-day period.

Brawn Biotech Q3 FY26 Results: Net Profit ₹0 Cr

Brawn Biotech Ltd reported net profit of ₹0 Cr for Q3 FY26.

Key figure

Net profit ₹0 Cr